51S.F CYNATA THERAPEUTICS

Healthcare Biotechnology Frankfurt Exchange
0.0070 EUR
Close of Nov 11, 2026
0.0005 0.2400
Market cap
EUR 2.36M
P/E
-
P/B
0.06x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is 51S.F undervalued?

Graham number

The Graham number of CYNATA THERAPEUTICS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CYNATA THERAPEUTICS fundamental analysis

No fundamental analysis for CYNATA THERAPEUTICS yet.

CYNATA THERAPEUTICS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CYNATA THERAPEUTICS

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for …

Full company profile